FiercePharma  Mar 19  Comment 
Should Salix Pharmaceuticals snap up its North Carolina neighbor Furiex Pharmaceuticals? The latter's bowel drug could slide right in to Salix's business, analysts said. And Furiex is scouting around for a potential buyer, Bloomberg reports.
SeekingAlpha  Feb 28  Comment 
Salix Pharmaceuticals (SLXP) Q4 2013 Earnings Call February 27, 2014 4:30 pm ET Executives G. Michael Freeman - Associate Vice President of Investor Relations & Corporate Communications Adam C. Derbyshire - Chief Financial Officer,...
StreetInsider.com  Feb 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Salix+Pharmaceuticals+Ltd+%28SLXP%29+Tops+Q4+EPS+by+13c%3B+Issues+Confident+FY14+Outlok/9226394.html for the full story.
DailyFinance  Feb 27  Comment 
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and RedHill Biopharma Ltd.(NASDAQ: RDHL; TASE: RDHL) today announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to...
DailyFinance  Feb 25  Comment 
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that a New York State Supreme Court jury has entered a verdict in its favor in a lawsuit filed against Salix by Napo Pharmaceuticals relating to Fulyzaq™ ...
Benzinga  Feb 21  Comment 
Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 20.78%. Akorn's revenue for the same period is $304.28 million. The...
TheStreet.com  Jan 24  Comment 
NEW YORK (TheStreet) -- Every successful investor is a contrarian: If the sum of all wisdom on a stock says it is worth $100 today, that price captures not just today's value but some future value as well. If you buy it in the expectation that is...
Wall Street Journal  Jan 13  Comment 
Salix Pharmaceuticals projects strong earnings for the year following its acquisition of fellow drug maker Santarus and the expansion of its sales force.
DailyFinance  Jan 13  Comment 
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today provided an update regarding business operations and FY2014 revenue and EPS guidance. Business Update The Company announced that, following the completion of its acquisition ...


Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company has a number of products currently approved for sales. These include Colazal (balsalazide disodium) for the treatment of mild to moderate active ulcerative colitis, Azasan (azathioprine) immuno-suppressive therapy for renal homo-transplant rejection and rheumatoid arthritis, and Anusol/Proctocort (hydrocortisone) for the relief of inflammatory dermatoses and hemorrhoids. In May 2004, the company received final Food and Drug Administration (FDA) approval for Xifaxan (rifaximin), an oral antibiotic for the treatment of traveler's diarrhea. Salix Pharmaceuticals is working on additional indications for Xifaxan, as well as a granulated formulation of mesalamine a common treatment option for ulcerative colitis.

Salix subsequently added new products to its portfolio including Visicol, indicated for colon cleansing prior to colonoscopy OsmoPrep, a next-generation Visicol which was launched in June 2006 and MoviPrep, a liquid bowel cleansing agent which was launched in October 2006. While Visicol and OsmoPrep were acquired by the company through its merger with InKine Pharmaceutical, exclusive U.S. in-licensing rights for MoviPrep were acquired from Norgine B.V. Recent additions to the product portfolio include Sanvar IR, indicated for the treatment of acute esophageal variceal bleeding (EVB) two hospital-based products, Pepcid Oral Suspension (indicated for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease) and Diuril Oral Suspension (an adjunctive therapy in edema associated with several conditions including hepatic cirrhosis), from Merck and metoclopramide Zydis, indicated for short term (4 12 weeks) therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

Salix focuses primarily on the U.S. pharmaceutical market, promoting its drugs through its specialized sales force. Management also seeks to form strategic alliances to market its products outside the U.S. in order to avoid the significant costs, risks, and infrastructure inherent in assembling an international sales force. Salix is located in Morrisville, NC and employs roughly 240 professionals.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki